Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
5
83%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

NCT03620474
completed

A Follow-up Evaluation Study of PRI-724-1101

NCT02828254
completedphase_1

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

NCT02195440
completedphase_1

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

NCT01764477
terminatedphase_1

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

NCT01302405
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03620474Phase 1

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Completed
NCT02828254

A Follow-up Evaluation Study of PRI-724-1101

Completed
NCT02195440Phase 1

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

Completed
NCT01764477Phase 1

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Completed
NCT01302405Phase 1

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

Terminated
NCT01606579Phase 1

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6